A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
This study is currently recruiting participants.
Verified July 2012 by Stanford University
Information provided by (Responsible Party):
First received: September 13, 2005
Last updated: July 5, 2012
Last verified: July 2012
- To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC).
- To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas.
- To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.
Head and Neck Cancers
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations|
Resource links provided by NLM:
Further study details as provided by Stanford University:
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186433
|Contact: Quynh-Thu Le||(650) email@example.com|
|United States, California|
|Stanford University School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Quynh-Thu Le 650-498-6184 firstname.lastname@example.org|
|Contact: Cancer Clinical Trials Office (650) 498-7061|
|Principal Investigator: Quynh-Thu Le|
|Sub-Investigator: Harlan Pinto|
|Sub-Investigator: James L Zehnder|
|Sub-Investigator: Dr. Billy W. Loo Jr. M.D. Ph.D.|
Sponsors and Collaborators
|Principal Investigator:||Quynh-Thu Le||Stanford University|